1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    




















































































































































































    Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation | American Journal of Neuroradiology  
    


















    































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      



          


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Review ArticleREVIEW ARTICLE

  
      
Open Access

  
      
Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation
  
    	
R.K. Rigsby, P. Brahmbhatt, A.B. Desai, G. Bathla, B.A. Ebner, V. Gupta, P. Vibhute and A.K. Agarwal

  
    	
American Journal of Neuroradiology March 2023,  DOI: https://doi.org/10.3174/ajnr.A7827 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵
    1. Louis  DN, 
    2. Perry  A, 
    3. Wesseling  P, et al
    . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076
    CrossRefPubMed
  2. 2.↵
    1. Louis  DN, 
    2. Aldape  K, 
    3. Brat  DJ, et al
    . cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 2017;27:851–52 doi:10.1111/bpa.12457 pmid:27997995
    CrossRefPubMed
  3. 3.↵
    1. Louis  DN, 
    2. Wesseling  P, 
    3. Paulus  W, et al
    . cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 2018;135:481–84 doi:10.1007/s00401-018-1808-0 pmid:29372318
    CrossRefPubMed
  4. 4.↵
    1. Louis  DN, 
    2. Giannini  C, 
    3. Capper  D, et al
    . cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–42 doi:10.1007/s00401-018-1826-y pmid:29497819
    CrossRefPubMed
  5. 5.↵
    1. Brat  DJ, 
    2. Aldape  K, 
    3. Colman  H, et al
    . cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 2018;136:805–10 doi:10.1007/s00401-018-1913-0 pmid:30259105
    CrossRefPubMed
  6. 6.↵
    1. Ellison  DW, 
    2. Hawkins  C, 
    3. Jones  DT, et al
    . cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 2019;137:683–87 doi:10.1007/s00401-019-01987-0 pmid:30848347
    CrossRefPubMed
  7. 7.↵
    1. Brat  DJ, 
    2. Aldape  K, 
    3. Colman  H, et al
    . cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020;139:603–08 doi:10.1007/s00401-020-02127-9 pmid:31996992
    CrossRefPubMed
  8. 8.↵
    1. Louis  DN, 
    2. Wesseling  P, 
    3. Aldape  K, et al
    . cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 2020;30:844–56 doi:10.1111/bpa.12832 pmid:32307792
    CrossRefPubMed
  9. 9.↵
    1. Ellison  DW, 
    2. Aldape  KD, 
    3. Capper  D, et al
    . cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 2020;30:863–66 doi:10.1111/bpa.12866 pmid:32502305
    CrossRefPubMed
  10. 10.↵
    1. Aboian  MS, 
    2. Solomon  DA, 
    3. Felton  E, et al
    . Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795–800 doi:10.3174/ajnr.A5076 pmid:28183840
    Abstract/FREE Full Text
  11. 11.↵
    1. Chen  Y, 
    2. Tian  T, 
    3. Guo  X, et al
    . Polymorphous low-grade neuroepithelial tumor of the young: case report and review focus on the radiological features and genetic alterations. BMC Neurol 2020;20:123 doi:10.1186/s12883-020-01679-3 pmid:32252664
    CrossRefPubMed
  12. 12.↵
    1. Bender  K, 
    2. Perez  E, 
    3. Chirica  M, et al
    . High-grade astrocytoma with piloid features (HGAP): the Charite experience with a new central nervous system tumor entity. J Neurooncol 2021;153:109–20 doi:10.1007/s11060-021-03749-z pmid:33905054
    CrossRefPubMed
  13. 13.↵
    1. Capper  D, 
    2. Jones  DTW, 
    3. Sill  M, et al
    . DNA methylation-based classification of central nervous system tumours. Nature 2018;555:469–74 doi:10.1038/nature26000 pmid:29539639
    CrossRefPubMed
  14. 14.↵
    1. Priesterbach-Ackley  LP, 
    2. Boldt  HB, 
    3. Petersen  JK, et al
    . Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. Neuropathol Appl Neurobiol 2020;46:478–92 doi:10.1111/nan.12610 pmid:32072658
    CrossRefPubMed
  15. 15.↵
    1. Osborn  AG, 
    2. Louis  DN, 
    3. Poussaint  TY, et al
    . The 2021 World Health Organization Classification of Tumors of the Central Nervous System: what neuroradiologists need to know. AJNR Am J Neuroradiol 2022;43:928–37 doi:10.3174/ajnr.A7462 pmid:35710121
    Abstract/FREE Full Text
  16. 16.↵
    1. Bale  TA, 
    2. Rosenblum  MK
    . The 2021 WHO Classification of Tumors of the Central Nervous System: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol 2022;32:e13060 doi:10.1111/bpa.13060 pmid:35218102
    CrossRefPubMed
  17. 17.↵
    1. Chiang  J, 
    2. Harreld  JH, 
    3. Tinkle  CL, et al
    . A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol 2019;138:1091–92 doi:10.1007/s00401-019-02081-1 pmid:31595312
    CrossRefPubMed
  18. 18.↵
    1. Huse  JT, 
    2. Snuderl  M, 
    3. Jones  DT, et al
    . Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 2017;133:417–29 doi:10.1007/s00401-016-1639-9 pmid:27812792
    CrossRefPubMed
  19. 19.↵
    1. Kurokawa  M, 
    2. Kurokawa  R, 
    3. Capizzano  AA, et al
    . Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature. Neuroradiology 2022;64:1255–64 doi:10.1007/s00234-021-02879-5 pmid:35001164
    CrossRefPubMed
  20. 20.↵
    1. Korshunov  A, 
    2. Capper  D, 
    3. Reuss  D, et al
    . Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016;131:137–46 doi:10.1007/s00401-015-1493-1 pmid:26482474
    CrossRefPubMed
  21. 21.↵
    1. Crowell  C, 
    2. Mata-Mbemba  D, 
    3. Bennett  J, et al
    . Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors. Neurooncol Adv 2022;4:vdac133 doi:10.1093/noajnl/vdac133 pmid:36105387
    CrossRefPubMed
  22. 22.↵
    1. Picart  T, 
    2. Barritault  M, 
    3. Poncet  D, et al
    . Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol Adv 2021;3:vdab061 doi:10.1093/noajnl/vdab061 pmid:34056608
    CrossRefPubMed
  23. 23.↵
    1. Kurokawa  R, 
    2. Baba  A, 
    3. Kurokawa  M, et al
    . Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: a case series and systematic review. J Neuroimaging 2022;32:17–27 doi:10.1111/jon.12939 pmid:34632671
    CrossRefPubMed
  24. 24.↵
    1. Korshunov  A, 
    2. Schrimpf  D, 
    3. Ryzhova  M, et al
    . H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol 2017;134:507–16 doi:10.1007/s00401-017-1710-1 pmid:28401334
    CrossRefPubMed
  25. 25.↵
    1. Tauziede-Espariat  A, 
    2. Debily  MA, 
    3. Castel  D, et al
    . An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN). Acta Neuropathol Commun 2019;7:87 doi:10.1186/s40478-019-0738-y pmid:31177990
    CrossRefPubMed
  26. 26.↵
    1. Tauziède-Espariat  A, 
    2. Debily  MA, 
    3. Castel  D, et al
    . The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts. Acta Neuropathol Commun 2020;8:104 doi:10.1186/s40478-020-00974-x pmid:32646492
    CrossRefPubMed
  27. 27.↵
    1. Guerreiro Stucklin  AS, 
    2. Ryall  S, 
    3. Fukuoka  K, et al
    . Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10:4343 doi:10.1038/s41467-019-12187-5 pmid:31554817
    CrossRefPubMed
  28. 28.↵
    1. Clarke  M, 
    2. Mackay  A, 
    3. Ismer  B, et al
    . Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10:942–63 doi:10.1158/2159-8290.CD-19-1030 pmid:32238360
    Abstract/FREE Full Text
  29. 29.↵
    1. Olsen  TK, 
    2. Panagopoulos  I, 
    3. Meling  TR, et al
    . Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? Neuro Oncol 2015;17:1365–73 doi:10.1093/neuonc/nov039 pmid:25795305
    CrossRefPubMed
  30. 30.↵
    1. McNamara  C, 
    2. Mankad  K, 
    3. Thust  S, et al
    . 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology 2022;64:1919–50 doi:10.1007/s00234-022-03008-6 pmid:35869291
    CrossRefPubMed
  31. 31.↵
    1. Fang  Y, 
    2. Wang  YZ, 
    3. Wei  X, et al
    . Infant-type hemispheric glioma in a Chinese girl: a newly defined entity. Fetal Pediatr Pathol 2023;42:114–22 doi:10.1080/15513815.2022.2142488 pmid:35404193
    CrossRefPubMed
  32. 32.↵
    1. Reinhardt  A, 
    2. Stichel  D, 
    3. Schrimpf  D, et al
    . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 2018;136:273–91 doi:10.1007/s00401-018-1837-8 pmid:29564591
    CrossRefPubMed
  33. 33.↵
    1. Lucas  CG, 
    2. Sloan  EA, 
    3. Gupta  R, et al
    . Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol 2022;144:747–65 doi:10.1007/s00401-022-02478-5 pmid:35945463
    CrossRefPubMed
  34. 34.↵
    1. Deng  MY, 
    2. Sill  M, 
    3. Sturm  D, et al
    . Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC): a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathol Appl Neurobiol 2020;46:422–30 doi:10.1111/nan.12590 pmid:31867747
    CrossRefPubMed
  35. 35.↵
    1. Pickles  JC, 
    2. Mankad  K, 
    3. Aizpurua  M, et al
    . A case series of diffuse glioneuronal tumours with oligodendroglioma-like features and nuclear clusters (DGONC). Neuropathol Appl Neurobiol 2021;47:464–67 doi:10.1111/nan.12680 pmid:33325069
    CrossRefPubMed
  36. 36.↵
    1. Solomon  DA, 
    2. Korshunov  A, 
    3. Sill  M, et al
    . Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathol 2018;136:339–43 doi:10.1007/s00401-018-1883-2 pmid:30006677
    CrossRefPubMed
  37. 37.↵
    1. Zamora  C, 
    2. Castillo  M
    . From dysembryoplastic neuroepithelial tumors to myxoid glioneuronal tumors, a new entity. AJNR Am J Neuroradiol 2021;42:E77–78 doi:10.3174/ajnr.A7273 pmid:34531194
    FREE Full Text
  38. 38.↵
    1. Lucas  CG, 
    2. Villanueva-Meyer  JE, 
    3. Whipple  N, et al
    . Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol 2020;30:479–94 doi:10.1111/bpa.12797 pmid:31609499
    CrossRefPubMed
  39. 39.↵
    1. Narvaez  EO, 
    2. Inada  BS, 
    3. de Almeida  P, et al
    . Myxoid glioneuronal tumour - report of three cases of a new tumour in a typical location and review of literature. BJR Case Rep 2021;7:20200139 doi:10.1259/bjrcr.20200139 pmid:35047190
    CrossRefPubMed
  40. 40.↵
    1. Choi  E, 
    2. Kim  SI, 
    3. Won  JK, et al
    . Clinicopathological and molecular analysis of multinodular and vacuolating neuronal tumors of the cerebrum. Hum Pathol 2019;86:203–12 doi:10.1016/j.humpath.2018.11.028 pmid:30550736
    CrossRefPubMed
  41. 41.↵
    1. Nunes  RH, 
    2. Hsu  CC, 
    3. da Rocha  AJ, et al
    . Multinodular and vacuolating neuronal tumor of the cerebrum: a new “Leave Me Alone” lesion with a characteristic imaging pattern. AJNR Am J Neuroradiol 2017;38:1899–904 doi:10.3174/ajnr.A5281 pmid:28705817
    Abstract/FREE Full Text
  42. 42.↵
    1. Buffa  GB, 
    2. Chaves  H, 
    3. Serra  MM, et al
    . Multinodular and vacuolating neuronal tumor of the cerebrum (MVNT): a case series and review of the literature. J Neuroradiol 2020;47:216–20 doi:10.1016/j.neurad.2019.05.010 pmid:31229580
    CrossRefPubMed
  43. 43.↵
    1. Alizada  O, 
    2. Ayman  T, 
    3. Akgun  MY, et al
    . Multinodular and vacuolating neuronal tumor of the cerebrum: Two cases and review of the literature. Clin Neurol Neurosurg 2020;197:106149 doi:10.1016/j.clineuro.2020.106149 pmid:32979644
    CrossRefPubMed
  44. 44.↵
    1. Turan  A, 
    2. Tatar  IG, 
    3. Hekimoglu  A, et al
    . Advanced magnetic resonance imaging findings of multinodular and vacuolating neuronal tumor. Turk Neurosurg 2021;31:725–30 doi:10.5137/1019-5149.JTN.32215-20.3 pmid:34169991
    CrossRefPubMed
  45. 45.↵
    1. Pajtler  KW, 
    2. Witt  H, 
    3. Sill  M, et al
    . Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015;27:728–43 doi:10.1016/j.ccell.2015.04.002 pmid:25965575
    CrossRefPubMed
  46. 46.↵
    1. Sun  S, 
    2. Wang  J, 
    3. Zhu  M, et al
    . Clinical, radiological, and histological features and treatment outcomes of supratentorial extraventricular ependymoma: 14 cases from a single center. J Neurosurg 2018;128:1396–402 doi:10.3171/2017.1.JNS161422 pmid:28686116
    CrossRefPubMed
  47. 47.↵
    1. Wang  J, 
    2. Wang  L, 
    3. Fu  L, et al
    . Supratentorial ependymoma with YAP1:FAM118B fusion: a case report. Neuropathology 2021;41:133–38 doi:10.1111/neup.12712 pmid:33480048
    CrossRefPubMed
  48. 48.↵
    1. Wang  X, 
    2. Han  F, 
    3. Lv  Y, et al
    . Supratentorial extraventricular ependymomas: imaging features and the added value of apparent diffusion coefficient. J Comput Assist Tomogr 2021;45:463–71 doi:10.1097/RCT.0000000000001164 pmid:34297516
    CrossRefPubMed
  49. 49.↵
    1. Jabeen  S, 
    2. Konar  SK, 
    3. Prasad  C, et al
    . Conventional and advanced magnetic resonance imaging features of supratentorial extraventricular ependymomas. J Comput Assist Tomogr 2020;44:692–98 doi:10.1097/RCT.0000000000001080 pmid:32842060
    CrossRefPubMed
  50. 50.↵
    1. Mariet  C, 
    2. Castel  D, 
    3. Grill  J, et al
    . Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis. Acta Neuropathol Commun 2022;10:137 doi:10.1186/s40478-022-01442-4 pmid:36104744
    CrossRefPubMed
  51. 51.↵
    1. Pajtler  KW, 
    2. Wen  J, 
    3. Sill  M, et al
    . Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 2018;136:211–26 doi:10.1007/s00401-018-1877-0 pmid:29909548
    CrossRefPubMed
  52. 52.↵
    1. Sabin  ND, 
    2. Hwang  SN, 
    3. Klimo  P   Jr., et al
    . Anatomic neuroimaging characteristics of posterior fossa type a ependymoma subgroups. AJNR Am J Neuroradiol 2021;42:2245–50 doi:10.3174/ajnr.A7322 pmid:34674998
    Abstract/FREE Full Text
  53. 53.↵
    1. Smith  AB, 
    2. Smirniotopoulos  JG, 
    3. Horkanyne-Szakaly  I
    . From the radiologic pathology archives: intraventricular neoplasms: radiologic-pathologic correlation. Radiographics 2013;33:21–43 doi:10.1148/rg.331125192 pmid:23322825
    CrossRefPubMed
  54. 54.↵
    1. Yonezawa  U, 
    2. Karlowee  V, 
    3. Amatya  VJ, et al
    . Radiology profile as a potential instrument to differentiate between posterior fossa ependymoma (PF-EPN) group A and B. World Neurosurg 2020;140:e320–27 doi:10.1016/j.wneu.2020.05.063 pmid:32428725
    CrossRefPubMed
  55. 55.↵
    1. Cavalli  FMG, 
    2. Hubner  JM, 
    3. Sharma  T, et al
    . Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018;136:227–37 doi:10.1007/s00401-018-1888-x pmid:30019219
    CrossRefPubMed
  56. 56.↵
    1. Raffeld  M, 
    2. Abdullaev  Z, 
    3. Pack  SD, et al
    . High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun 2020;8:101 doi:10.1186/s40478-020-00973-y pmid:32641156
    CrossRefPubMed
  57. 57.↵
    1. Swanson  AA, 
    2. Raghunathan  A, 
    3. Jenkins  RB, et al
    . Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol 2019;78:791–97 doi:10.1093/jnen/nlz064 pmid:31373367
    CrossRefPubMed
  58. 58.↵
    1. Ghasemi  DR, 
    2. Sill  M, 
    3. Okonechnikov  K, et al
    . MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 2019;138:1075–89 doi:10.1007/s00401-019-02056-2 pmid:31414211
    CrossRefPubMed
  59. 59.↵
    1. Celano  E, 
    2. Salehani  A, 
    3. Malcolm  JG, et al
    . Spinal cord ependymoma: a review of the literature and case series of ten patients. J Neurooncol 2016;128:377–86 doi:10.1007/s11060-016-2135-8 pmid:27154165
    CrossRefPubMed
  60. 60.↵
    1. Koeller  KK, 
    2. Rosenblum  RS, 
    3. Morrison  AL
    . Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. Radiographics 2000;20:1721–49 doi:10.1148/radiographics.20.6.g00nv151721 pmid:11112826
    CrossRefPubMedWeb of Science
  61. 61.↵
    1. Hasselblatt  M, 
    2. Oyen  F, 
    3. Gesk  S, et al
    . Cribriform neuroepithelial tumor (CRINET): a nonrhabdoid ventricular tumor with INI1 loss and relatively favorable prognosis. J Neuropathol Exp Neurol 2009;68:1249–55 doi:10.1097/NEN.0b013e3181c06a51 pmid:19915490
    CrossRefPubMed
  62. 62.↵
    1. Tauziède-Espariat  A, 
    2. Guerrini-Rousseau  L, 
    3. Puget  S, et al
    . A novel case of cribriform neuroepithelial tumor: a potential diagnostic pitfall in the ventricular system. Pediatr Blood Cancer 2021;68:e29037 doi:10.1002/pbc.29037 pmid:34151521
    CrossRefPubMed
  63. 63.↵
    1. Arnold  MA, 
    2. Stallings-Archer  K, 
    3. Marlin  E, et al
    . Cribriform neuroepithelial tumor arising in the lateral ventricle. Pediatr Dev Pathol 2013;16:301–07 doi:10.2350/12-12-1287-CR.1 pmid:23495723
    CrossRefPubMed
  64. 64.↵
    1. Pawel  BR
    . SMARCB1-deficient tumors of childhood: a practical guide. Pediatr Dev Pathol 2018;21:6–28 doi:10.1177/1093526617749671 pmid:29280680
    CrossRefPubMed
  65. 65.↵
    1. Johann  PD, 
    2. Hovestadt  V, 
    3. Thomas  C, et al
    . Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathol 2017;27:411–18 doi:10.1111/bpa.12413 pmid:27380723
    CrossRefPubMed
  66. 66.↵
    1. Ruland  V, 
    2. Hartung  S, 
    3. Kordes  U, et al
    . Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis. Genes Chromosomes Cancer 2014;53:373–80 doi:10.1002/gcc.22148 pmid:24478045
    CrossRefPubMed
  67. 67.↵
    1. Sturm  D, 
    2. Orr  BA, 
    3. Toprak  UH, et al
    . New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016;164:1060–72 doi:10.1016/j.cell.2016.01.015 pmid:26919435
    CrossRefPubMed
  68. 68.↵
    1. Li  X, 
    2. Wang  W, 
    3. Xi  Y, et al
    . FOXR2 interacts with MYC to promote its transcriptional activities and tumorigenesis. Cell Rep 2016;16:487–97 doi:10.1016/j.celrep.2016.06.004 pmid:27346356
    CrossRefPubMed
  69. 69.↵
    1. Tietze  A, 
    2. Mankad  K, 
    3. Lequin  MH, et al
    . Imaging characteristics of CNS neuroblastoma-FOXR2: a retrospective and multi-institutional description of 25 cases. AJNR Am J Neuroradiol 2022;43:1476–80 doi:10.3174/ajnr.A7644
    Abstract/FREE Full Text
  70. 70.↵
    1. Cardoen  L, 
    2. Tauziède-Espariat  A, 
    3. Dangouloff-Ros  V, et al
    . Imaging features with histopathologic correlation of CNS high-grade neuroepithelial tumors with a BCOR internal tandem duplication. AJNR Am J Neuroradiol 2022;43:151–56 doi:10.3174/ajnr.A7367 pmid:34887247
    Abstract/FREE Full Text
  71. 71.↵
    1. Matsumura  N, 
    2. Goda  N, 
    3. Yashige  K, et al
    . Desmoplastic myxoid tumor, SMARCB1-mutant: a new variant of SMARCB1-deficient tumor of the central nervous system preferentially arising in the pineal region. Virchows Arch 2021;479:835–39 doi:10.1007/s00428-020-02978-3 pmid:33420834
    CrossRefPubMed
  72. 72.↵
    1. Thomas  C, 
    2. Wefers  A, 
    3. Bens  S, et al
    . Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathol 2020;139:277–86 doi:10.1007/s00401-019-02094-w pmid:31732806
    CrossRefPubMed
  73. 73.↵
    1. Wang  YE, 
    2. Chen  JJ, 
    3. Wang  W, et al
    . A case of desmoplastic myxoid tumor, SMARCB1 mutant, in the pineal region. Neuropathology 2021;41:37–41 doi:10.1111/neup.12695 pmid:32901946
    CrossRefPubMed
  74. 74.↵
    1. Sloan  EA, 
    2. Chiang  J, 
    3. Villanueva-Meyer  JE, et al
    . Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. Brain Pathol 2021;31:e12918 doi:10.1111/bpa.12918 pmid:33141488
    CrossRefPubMed
  75. 75.↵
    1. Sbaraglia  M, 
    2. Righi  A, 
    3. Gambarotti  M, et al
    . Ewing sarcoma and Ewing-like tumors. Virchows Arch 2020;476:109–19 doi:10.1007/s00428-019-02720-8 pmid:31802230
    CrossRefPubMed
  76. 76.↵
    1. Kallen  ME, 
    2. Hornick  JL
    . The 2020 WHO Classification: what’s new in soft tissue tumor pathology? Am J Surg Pathol 2021;45:e1–e23 doi:10.1097/PAS.0000000000001552 pmid:32796172
    CrossRefPubMed
  77. 77.↵
    1. Yoshida  A, 
    2. Goto  K, 
    3. Kodaira  M, et al
    . CIC-rearranged sarcomas: a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol 2016;40:313–23 doi:10.1097/PAS.0000000000000570 pmid:26685084
    CrossRefPubMed
  78. 78.↵
    1. Le Loarer  F, 
    2. Pissaloux  D, 
    3. Watson  S, et al
    . Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. Am J Surg Pathol 2019;43:268–76 doi:10.1097/PAS.0000000000001187 pmid:30407212
    CrossRefPubMed
  79. 79.↵
    1. Donahue  JE, 
    2. Yakirevich  E, 
    3. Zhong  S, et al
    . Primary spinal epidural CIC-DUX4 undifferentiated sarcoma in a child. Pediatr Dev Pathol 2018;21:411–17 doi:10.1177/1093526617707856 pmid:28474974
    CrossRefPubMed
  80. 80.↵
    1. Song  K, 
    2. Huang  Y, 
    3. Xia  CD, et al
    . A case of CIC-rearranged sarcoma with CIC-LEUTX gene fusion in spinal cord. Neuropathology 2022;42:555–62 doi:10.1111/neup.12850 pmid:35859319
    CrossRefPubMed
  81. 81.↵
    1. Hu  W, 
    2. Wang  J, 
    3. Yuan  L, et al
    . Case report: a unique case of pediatric central nervous system embryonal tumor harboring the CIC-LEUTX fusion, germline NBN variant and somatic TSC2 mutation: expanding the spectrum of CIC-rearranged neoplasia. Front Oncol 2020;10:598970 doi:10.3389/fonc.2020.598970 pmid:33344249
    CrossRefPubMed
  82. 82.↵
    1. Kamihara  J, 
    2. Paulson  V, 
    3. Breen  MA, et al
    . DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol 2020;33:1910–21 doi:10.1038/s41379-020-0516-1 pmid:32291395
    CrossRefPubMed
  83. 83.↵
    1. Lee  JC, 
    2. Villanueva-Meyer  JE, 
    3. Ferris  SP, et al
    . Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol 2019;137:521–25 doi:10.1007/s00401-019-01960-x pmid:30649606
    CrossRefPubMed
  84. 84.↵
    1. Diaz Coronado  RY, 
    2. Mynarek  M, 
    3. Koelsche  C, et al
    . Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer 2022;128:697–707 doi:10.1002/cncr.33977 pmid:34674226
    CrossRefPubMed
  85. 85.↵
    1. de Kock  L, 
    2. Priest  JR, 
    3. Foulkes  WD, et al
    . An update on the central nervous system manifestations of DICER1 syndrome. Acta Neuropathol 2020;139:689–701 doi:10.1007/s00401-019-01997-y pmid:30953130
    CrossRefPubMed
  86. 86.↵
    1. Leelatian  N, 
    2. Goss  J, 
    3. Pastakia  D, et al
    . Primary intracranial sarcoma, DICER1-mutant presenting as a pineal region tumor mimicking pineoblastoma: case report and review of the literature. J Neuropathol Exp Neurol 2022;81:762–64 doi:10.1093/jnen/nlac053 pmid:35789272
    CrossRefPubMed
  87. 87.↵
    1. Rashidi  A, 
    2. Luna  LP, 
    3. Rodriguez  F, et al
    . Teaching NeuroImages: intracranial DICER1-associated spindle cell sarcoma in a child. Neurology 2020;95:e2176–77 doi:10.1212/WNL.0000000000010374 pmid:32680948
    CrossRefPubMed
  88. 88.↵
    1. Shih  RY, 
    2. Schroeder  JW, 
    3. Koeller  KK
    . Primary tumors of the pituitary gland: radiologic-pathologic correlation. Radiographics 2021;41:2029–46 doi:10.1148/rg.2021200203 pmid:34597177
    CrossRefPubMed
  89. 89.↵
    1. Chhuon  Y, 
    2. Weon  YC, 
    3. Park  G, et al
    . Pituitary blastoma in a 19-year-old woman: a case report and review of literature. World Neurosurg 2020;139:310–13 doi:10.1016/j.wneu.2020.04.096 pmid:32339726
    CrossRefPubMed
  90. 90.↵
    1. Liu  AP, 
    2. Kelsey  MM, 
    3. Sabbaghian  N, et al
    . Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab 2021;106:351–63 doi:10.1210/clinem/dgaa857 pmid:33236116
    CrossRefPubMed
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation
  
    	
R.K. Rigsby, P. Brahmbhatt, A.B. Desai, G. Bathla, B.A. Ebner, V. Gupta, P. Vibhute, A.K. Agarwal

  
    	
 American Journal of Neuroradiology Mar 2023, DOI: 10.3174/ajnr.A7827 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement